<DOC>
	<DOCNO>NCT02565615</DOCNO>
	<brief_summary>The study verify atorvastatin effectiveness safety Chinese population , explore optimal atorvastatin regimens high-to-moderate risk ASCVD。</brief_summary>
	<brief_title>Atorvastatin Effectiveness Safety Cardiology Patients Real World Setting</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Men woman age ≥18 year ; Cardiology patient prescribe atorvastatin physician 's clinical judgment normal clinical care . These patient include establish coronary heart disease , multiple risk factor risk cardiovascular disease , primary hypercholesterolemia . Baseline laboratory report prior start atorvastatin therapy track , include lipid measurement , liver function , Creatine Kinase ( CK ) value . The date baseline report within 1 month take atorvastatin . Evidence personally his/her legally acceptable representative sign date informed consent document indicate patient inform pertinent aspect study accept followup visit . Patients regularly take atorvastatin therapy 4 week enrollment Concomitant lipidlower medication baseline , study conduction physician clinical judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>